Zydus Lifesciences Ltd
Zydus Lifesciences Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business. Zydus Lifesciences projects strong double-digit revenue growth for FY27, with continued mid-teens growth in the India business and single-digit growth internationally.
From Zydus Lifesciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business.
- India formulation business: 20% growth in branded portfolio; chronic therapies and innovation portfolios driving sustainable momentum.
- International markets (EM and Europe): Continued strong growth with new market entries scaling faster than expected.
- US business: Single-digit growth expected this year, with potential for double-digit growth in FY28 driven by pipeline and branded product scaling.
- Consumer Wellness: Strong double-digit growth anticipated, continuing 25% like-to-like growth internationally.
- Medical devices: Growth through investment in focused therapies and differentiation.
- Medium term: Branded portfolio expected to exceed two-thirds of total revenue, driving improved growth and profitability.
- Biosimilars: Already meaningfully scaled and profitable, contributing to growth.
- Innovation assets, including Saroglitazar US launch (FY28) and specialty products, are key future growth drivers.
Profitability & Margins
See what Zydus Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for the full year is around ₹1,500-₹1,600 crores.
- Investments include:
- - Expansion of existing facilities: Moraiya, Goa, Baddi, Unit-2 and Unit-3 at SEZ.
- - New formulation R&D center for development.
- - One-time land acquisition for wellness business expansion.
- - New CAR-T facility for biologics.
- - New vaccines DS (Drug Substance) facility.
- - Continued investment in Zylidac.
- Saro (Saroglitazar US launch) will require investments primarily in FY27 and FY28, with build-out phase for first 2 years post-launch in FY28.
- MedTech and specialty businesses are already invested and baked into current margin guidance.
- Investments are spread across multiple areas to increase scale and capability, no single large capex item except wellness land acquisition.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q1 FY27 results?
FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business. Zydus Lifesciences projects strong double-digit revenue growth for FY27, with continued mid-teens growth in the India business and single-digit growth internationally.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.9 with a market cap of ₹111,720 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
Capex guidance for the full year is around ₹1,500-₹1,600 crores.
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.